유니사이시브 테라퓨틱스(UNCY)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.83 (+1.26%), 시가총액 $0.20B, 52주 최저~최고 $0.53 ~ $8.56.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, Ca
유니사이시브 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
유니사이시브 테라퓨틱스의 현재 주가는 $4.83 (+1.26%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
유니사이시브 테라퓨틱스의 시가총액은 약 $0.20B입니다.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanth